Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study.
Jiang B, Ke X, Zhang Q, Xu W, Su H, Huang J, Zhang M, Wang H, Jin C, Zhu J, Liu L, Cai Z, Zhao X, Zhou J, Zhang X, Liu J, Zhou H, Yu J, Sun X, Qi J, Qiu L.
Jiang B, et al. Among authors: liu j, liu l.
Sci Rep. 2020 Jul 15;10(1):11676. doi: 10.1038/s41598-020-68360-0.
Sci Rep. 2020.
PMID: 32669656
Free PMC article.
Clinical Trial.